102 results match your criteria: "City of Hope National Cancer Center.[Affiliation]"
Front Oncol
November 2024
Department of Obstetrics and Gynecology, University of California Irvine School of Medicine, Irvine, CA, United States.
The discovery of gene fusions involving Neuregulin-1 () within solid tumors has important therapeutic implications, as they are being actively explored as targets for emerging ERBB/ERBB2/ERBB3-directed anti-cancer agents. fusions are very uncommon across all tumor types and are infrequently documented in the medical literature. We report a female patient presenting with widespread peritoneal carcinomatosis diagnosed as high grade serous fallopian tube carcinoma, which harbored a previously undescribed :: fusion.
View Article and Find Full Text PDFMagn Reson Med
November 2024
Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Transl Gastroenterol Hepatol
August 2024
Department of Surgery, City of Hope National Cancer Center, Duarte, CA, USA.
Pract Radiat Oncol
January 2024
Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California; Beckman Research Institute, City of Hope National Cancer Center, Duarte, California.
Prostate Cancer Prostatic Dis
October 2024
Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC, USA.
Transl Cancer Res
August 2024
Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background: Cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) are the most commonly used tumor biomarkers for ovarian cancer (OC) screening and diagnosis. The risk of ovarian malignancy algorithm (ROMA) score uses these markers, as detected by the Roche system, to predict the risk of OC. This study sought to assess the performance of the Mindray system in detecting CA125 and HE4 for ROMA score calculation in clinical settings.
View Article and Find Full Text PDFHaematologica
January 2025
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Support Care Cancer
June 2024
Department for Global Health and Rehabilitation, Western Norway University of Applied Sciences, Bergen, Norway.
Purpose: The number of older people with poor oral health diagnosed with cancer is increasing rapidly. However, integration of oral health in cancer care for older people to prevent or minimize oral health complications of cancer treatments is uncommon, except in head and neck oncology. The aim of this review is to describe the need, role of, and factors influencing the integration of oral health(care) into the treatment of older people with cancer.
View Article and Find Full Text PDFPract Radiat Oncol
November 2024
Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California; Beckman Research Institute, City of Hope National Cancer Center, Duarte, California. Electronic address:
Exposure to radiation oncology (RO), which is a small and highly subspecialized field of oncology, during undergraduate or medical education is often limited. Coupled with reduced elective exposures during the COVID-19 pandemic, unsubstantiated concerns regarding the RO job market have led to a noticeable decline in residency applications and medical students who express an interest in the field. Here, we describe a summer education program piloted in our RO department at a comprehensive cancer center to provide premedical school students (ranging from high school to postbaccalaureate) early exposure to the specialty through clinical shadowing, research opportunities, journal club, and formal didactic lectures.
View Article and Find Full Text PDFExpert Opin Pharmacother
April 2024
Lifespan Cancer Institute, Providence, RI, USA.
Introduction: The introduction of targeted therapy and immunotherapy has tremendously changed the clinical outcomes and prognosis of cancer patients. Despite innovative pharmacological therapies and improved radiotherapy (RT) techniques, patients continue to suffer from side effects, of which oral mucositis (OM) is still the most impactful, especially for quality of life.
Areas Covered: We provide an overview of current advances in cancer pharmacotherapy and RT, in relation to their potential to cause OM, and of the less explored and more recent literature reports related to the best management of OM.
Int J Radiat Oncol Biol Phys
September 2024
Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California. Electronic address:
Purpose: Limited studies have described the utilization of cannabinoids among patients with cancer. This survey study aimed to characterize utilization patterns and perceptions of cannabinoid use for treatment-related side effects among patients receiving radiation treatment.
Methods And Materials: This was an anonymous survey study of patients who were undergoing or recently completed radiation treatment at a comprehensive cancer center.
Support Care Cancer
March 2024
Faculty of Dental Medicine and Oral Health, McGill University, Montreal, QC, Canada.
Purpose: Medication-related osteonecrosis of the jaw (MRONJ) is a debilitating side effect of antiresorptive and antiangiogenic agents that can lead to progressive bone destruction in the maxillofacial region. Dental surgery, including tooth extractions, commonly trigger the onset of MRONJ. While guidelines suggest avoiding extraction when possible, complete avoidance is not always feasible, as necrosis can develop from dental and periodontal disease without dental procedures.
View Article and Find Full Text PDFPract Radiat Oncol
March 2024
Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California. Electronic address:
Whole-brain radiation treatment is often considered for patients with leptomeningeal disease. There are limited reports of the development of radiation necrosis after whole-brain radiation treatment and fewer associating the presence of germline mutations with risk. We present a case report to highlight the need for consideration of radiosensitizing mutations when recommending radiation therapy.
View Article and Find Full Text PDFJ Thorac Oncol
June 2024
Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut. Electronic address:
Introduction: Durvalumab improves survival when used as consolidation therapy after chemoradiation (CRT) in patients with stage III NSCLC. The optimal consolidation therapy for patients with EGFR-mutant (EGFRmut) stage III NSCLC remains unknown.
Methods: In this multi-institutional, international retrospective analysis across 24 institutions, we evaluated outcomes in patients with stage III EGFRmut NSCLC treated with concurrent CRT followed by consolidation therapy with osimertinib, durvalumab, or observation between 2015 and 2022.
Int J Radiat Oncol Biol Phys
January 2024
Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California; Beckman Research Institute, City of Hope National Cancer Center, Duarte, California. Electronic address:
Clin Lung Cancer
November 2023
Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, CA. Electronic address:
Background And Purpose: The role of stereotactic body radiation therapy (SBRT) in oligoprogressive non-small-cell lung cancer (NSCLC) is controversial. We evaluated whether SBRT in a subset of patients with oligoprogressive or oligorecurrent NSCLC offers a durable response, obviating the need to change systemic therapy.
Methods: A retrospective analysis of 168 NSCLC patients who underwent SBRT for oligoprogressive or oligorecurrent disease was performed.
Genes Dis
March 2024
Hereditary Cancer Program, Catalan Institute of Oncology, Oncobell Program, IDIBELL, Hospitalet de Llobregat, Barcelona 08908, Spain.
Background: The phase 3 of JAVELIN Bladder 100 trial demonstrated that avelumab first-line (1L) maintenance in addition to best supportive care significantly prolonged overall survival compared to best supportive care alone. It is now the standard of care for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma that has not progressed with 1L platinum-containing chemotherapy.
Objectives: This article provides considerations for oncology nurses to effectively implement avelumab 1L maintenance treatment in the clinical setting.
Pract Radiat Oncol
March 2024
Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California; Department of Urology, University of California Los Angeles, Los Angeles, California. Electronic address:
Traditionally, external beam radiotherapy (EBRT) for localized prostate cancer (PCa) involved lengthy courses with low daily doses. However, advancements in radiation delivery and a better understanding of prostate radiobiology have enabled the development of shorter courses of EBRT. Ultrahypofractionated radiotherapy, administering doses greater than 5 Gy per fraction, is now considered a standard of care regimen for localized PCa, particularly for intermediate-risk disease.
View Article and Find Full Text PDFJ Med Chem
October 2023
Department of Pharmacy, Epigenetic Med Chem Lab, University of Salerno, via Giovanni Paolo II 132, Fisciano ,I-84084 SA Italy.
Methods Mol Biol
May 2023
Department of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope National Cancer Center, Duarte, CA, USA.
R-loops are three-stranded nucleic acid structures that consist of a DNA-RNA hybrid and a displaced single-stranded DNA. Since it was first reported by Ronald Davis and colleagues over 40 years ago, the study of R-loops has become an increasingly expanded area of research. Numerous factors have been identified to modulate the dynamic formation and resolution of R-loops, which are critical for proper controls of gene expression and genome stability.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
April 2023
Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California.
Front Oncol
February 2023
Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Cancer Center, Duarte, CA, United States.
JCO Precis Oncol
September 2022
Invitae, San Francisco, CA.
Prostate Cancer Prostatic Dis
April 2022
City of Hope National Cancer Center, Duarte, CA, USA.